Shilpa Medicare’s JV Oncosol gets USFDA approval for IMKELDI
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
The product will be marketed by Dr. Reddy's
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
Dr. Muthu was last associated with Mankind Pharma
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
Subscribe To Our Newsletter & Stay Updated